Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down – Here’s Why

Dyne Therapeutics, Inc. (NASDAQ:DYN) gapped down before the market opened on Thursday . The stock had previously closed at $32.36, but opened at $31.33. Dyne Therapeutics shares last traded at $31.93, with a volume of 67,167 shares traded.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DYN. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Piper Sandler reaffirmed an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Oppenheimer restated an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Stifel Nicolaus increased their price objective on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $50.60.

Dyne Therapeutics Trading Down 3.2 %

The stock has a fifty day simple moving average of $36.92 and a 200-day simple moving average of $34.66. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -8.15 and a beta of 1.05.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Susanna Gatti High sold 8,976 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the sale, the chief operating officer now directly owns 131,636 shares in the company, valued at approximately $4,529,594.76. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Dirk Kersten sold 79,411 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the sale, the director now owns 234,127 shares of the company’s stock, valued at $8,533,929.15. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 158,975 shares of company stock worth $5,693,789. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC boosted its holdings in shares of Dyne Therapeutics by 4.3% during the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after buying an additional 352 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Dyne Therapeutics by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of Dyne Therapeutics by 5.9% during the first quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock worth $437,000 after acquiring an additional 857 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.